Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eflornithine + interferon alpha-2a
- Development stage
- Discontinued
- Lead developer
- Mayo Clinic
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
A combination therapy consisting of eflornithine (an irreversible ornithine decarboxylase inhibitor) and interferon alpha-2a (a recombinant interferon). This combination was studied for the treatment of recurrent glioma based on in vitro evidence suggesting synergistic effects between the two agents. Eflornithine works by irreversibly binding to ornithine decarboxylase, reducing cellular polyamine levels, while interferon alpha-2a helps the immune system fight infections and has potential anti-tumor properties.
- Other names
- DFMO + interferon alpha-2aα-difluoromethylornithine + interferon alpha-2a
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)ODC1 (Ornithine decarboxylase)
Beyond the preview
Go deeper on eflornithine + interferon alpha-2a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eflornithine + interferon alpha-2a.